Search PubMedSearch

PubMed · 2359936

[Prostatitis].

Abstract

Infection of the prostatic gland tissue is frequent, affecting from 4 to 5% of men according to anatomical studies. The classical distinction between acute and chronic prostatitis still too often suggests different diseases, whereas chronic prostatitis in fact is the clinical expression of an initial acute or subacute infection for lack of diagnosis and therefore of an appropriate and sufficiently prolonged treatment. In both acute and chronic prostatitis the pathogens are the same: E. coli at all ages, organisms causing urethritis in young men, Gram-negative and often multiresistant bacilli in iatrogenic infections. Fluoroquinolones, which are active against most of these bacteria and are present in high concentrations in the prostate, are for the moment among the most effective antibacterial agents. But unless they are prescribed at an early stage and for long periods prostatitis may remain a desperately chronic disease.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Remy. 1990-05-11. [Prostatitis].. https://pubmed.ncbi.nlm.nih.gov/2359936/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Synthesis and antibacterial activity of 1-(substituted pyrrolyl)-7-(substituted amino)-6-fluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids.

Seventeen quinolone compounds characterized by having a fluorine atom at the 6-position, a substituted amino at the 7-position, and a substituted pyrrolyl at the 1-position were synthesized for the first time. The in vitro antibacterial activities of these compounds against Escherichia coli and Staphylococcus aureus were tested. Among these agents obtained, compound 24 showed significantly enhanced activity against S. aureus. The results indicate that there is much room for modifications at the N-1 position.

4-Quinolones

Future directions in antimicrobial chemotherapy.

New developments in the treatment of bacterial infections are discussed. The most important developments include oral broad-spectrum cephalosporin derivatives and extended-spectrum injectable cephalosporins with improved activity against Gram-positive bacteria. Meropenem is a new carbapenem agent with markedly improved activity against Gram-negative bacteria. Many fluoroquinolones are in various phases of development. The most interesting new compound is sparfloxacin. Azithromycin is a new macrolide which, because of its very long half-life, attains very high levels in most tissues. Potential uses of the newer agents are discussed.

4-Quinolones

New drugs for infections in patients with cancer.

BACKGROUND: During the past several years, the treatment and prevention of infections in patients with cancer have improved because of the development of new antimicrobial drugs. METHODS: A representative antibacterial, antifungal, and antiviral drug is discussed. RESULTS: The fluoroquinolone compounds, such as ciprofloxacin, norfloxacin, and ofloxacin, have broad spectrum bactericidal activity and have proved to be effective in both the treatment and prevention of certain infections in patients with cancer. The triazole drug fluconazole is useful in the treatment of oral, esophageal, and disseminated candidiasis and cryptococcal meningitis. Early studies suggest that a new acyclic nucleoside, ganciclovir, has some effect in the treatment of cytomegalovirus infections, but its precise use in patients with cancer has not been fully established. CONCLUSIONS: New drugs currently available to the practitioner will improve management of infections in patients with cancer, but none is totally effective and the search for new compounds must continue.

4-Quinolones